Umecrine AB’s business concept is to develop antagonists to CNS-active steroids (GABA-steroids) to reduce symptoms and conditions caused by endogenous sex and stress hormons on the brain. This is a unique and novel treatment principle based on modulation of GABA-steroid action.
The company strategy is to bring componds into development and then out-license, or seek a strategic partnership or an M&A transaction with a company searching for a new opportunity within the field of CNS or Women’s Health.